He also found that the clinical designation of estrogen receptor-negative breast carcinoma encompassed at least two distinct subtypes of tumors (basal-like and ErB-B2-positive), which he stated may need to be treated as distinct diseases [9]. Here, ERBB2 is linked to breast carcinoma.